SMC 021 fails Phase III trial for Post Menopausal Osteoporosis

SMC 021, an oral salmon calctonin from Novartis, failed to meet main fracture reduction endpoints in Study 2303 a study of Post Menopausal Osteoporosis and to demonstrate a significant difference between treatment groups at three years for the primary endpoint of reducing new vertebral fractures. Similarly no statistical significant response was observed on key secondary endpoints such as new non-vertebral fractures or new clinical fractures.